FPT-CORPORATION
FPT Corporation (FPT) has acquired the IT services company Next Advanced Communications NAC Co., Ltd. (NAC), making it FPT’s first merger & acquisition (M&A) deal in Japan. With NAC as FPT’s wholly-owned subsidiary, the company aims to double its customer base and service offerings, deepening its foothold in the Japanese market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229752610/en/
The strategic investment signing ceremony between NAC and FPT took place in Tokyo, Japan (Photo: Business Wire)
The strategic move aligns with FPT’s global expansion strategy and enables the Vietnamese firm to capitalize on NAC’s talent pool of nearly 300 experienced engineers and strong expertise centred on technology and business consulting, architecture design, system planning, design, development, and operation. With these additional resources, FPT aims to achieve one billion USD in revenue from the Japanese market by 2027 and have more than half of its employees in Japan as multinational employees.
With current challenges for digital transformation in Japan, including an ageing population, shortage of ICT human resources and complexity of existing systems, the acquisition of NAC reflects FPT’s commitment to accompanying Japanese businesses in digital transformation and green transformation. This also enables FPT to foster sustainable growth and competitiveness and expand its services to new industries and a wider range of customers.
"Like NAC, FPT strives to leverage technology to address a variety of customer issues, with the goal of creating a sustainable society for everyone. We aim to enhance the Japanese engineer talent pool and cooperate with local companies to help our clients maintain business continuity despite geopolitical challenges. Additionally, FPT prioritizes and fosters a multicultural work environment. I believe NAC and FPT employees will find greater success and happiness in our collaboration," said Do Van Khac, FPT Software Senior Executive Vice President and FPT Japan CEO.
Naoto Yamazaki, NAC Chairman, said: “Since we started NAC 13 years ago, we have achieved success as an independent company. Today, as we join the FPT family, I believe not only can we maintain our growth but also form a stronger synergy for the future. NAC and FPT will strive to accelerate our business more than ever and become a company that can contribute to society.”
Since 2014, FPT has completed multiple M&A deals in the US and Europe. In Japan, the firm recently formed a joint venture with Konica Minolta and made a strategic investment in LTS Inc. The acquisition of NAC, as FPT’s first M&A deal in Japan, highlights its focused, long-term commitment to this key market. This also generates momentum for the corporation’s future M&A activities.
FPT has nearly two decades of presence in the Japanese market with the operation of FPT Japan, one of the country’s largest foreign-invested tech firms in terms of human resources. With a workforce of 2,900 onsite employees, nearly 15,000 employees working from overseas, 16 local offices and innovation hubs, FPT Japan has provided services and solutions to over 450 clients worldwide. The company is also recognized for excellent employee benefits and workplace happiness, earning accolades such as Best Workplaces in Asia, Best Places To Work in Japan, and Best Places To Work for Women in Japan.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 70,000+ employees. For more information, please visit https://fpt.com.vn/en.
About NAC Co., Ltd.
NAC Co., Ltd. was established on March 31, 2011. The company's main businesses are marketing, consulting support, system planning, and system design, development, operation, and maintenance. By providing these services, NAC aims to realize a sustainable future as a member of the FPT Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229752610/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom